Literature DB >> 1349911

Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts.

R M Herings1, A Bakker, B H Stricker, G Nap.   

Abstract

STUDY
OBJECTIVES: The aims were (1) to compare discharge diagnoses and concurrent medication in a pharmacy based cohort of users of H2 receptor antagonists to those in a population of users of other drugs in the same period, who did not use H2 receptor antagonists; (2) to compare these results to those of a similar study performed with the Tayside record linkage scheme. DESIGN AND
SETTING: The study was a retrospective cohort study. The morbidity data from the only hospital in one medium sized city (62,000 inhabitants) were linked to the dispensing data of all five community pharmacies on an individual basis (April 1, 1986-December 31, 1989). In the absence of a unique patient identification number, data from pharmacies and hospital were linked by the combination of date of birth, gender, and general practitioner code. For every user of H2 receptor antagonists two controls were obtained from all patients who had not used these drugs, and matched for age (within 5 years), gender, and general practitioner. All discharge diagnoses which followed this first prescription up to December 31, 1989, in a patient in the index cohort, and during the same period in his or her matched controls, were included in the study. MAIN
RESULTS: In the index cohort (n = 2174) 341 persons were admitted (526 admissions) as against 398 persons (527 admissions) in the control cohort (n = 4348). There was increased morbidity in the index cohort, especially concerning the gastrointestinal system (peptic ulcers and malignancies, abdominal pain, gastrointestinal haemorrhage), but also concerning the musculoskeletal, respiratory, and circulatory systems. The morbidity in the last three groups corresponded with drugs used concomitantly by patients in the index cohort, so it was probably not causally related to the intake of H2 receptor antagonists but was rather an indicator of higher levels of morbidity in the index cohort.
CONCLUSIONS: The figures were grossly comparable to those of the Tayside record linkage scheme. Probabilistic linking with the patient characteristics of gender, date of birth, and general practitioner code can facilitate the undertaking of postmarketing surveillance studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349911      PMCID: PMC1059521          DOI: 10.1136/jech.46.2.136

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  7 in total

1.  Recording of drug prescriptions in the county of Jämtland, Sweden. II. Drug exposure of pregnant women in relation to course and outcome of pregnancy.

Authors:  G Boethius
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

Review 2.  Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation.

Authors:  D G Jones; M J Langman; D H Lawson; M P Vessey
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

3.  The California Automated Mortality Linkage System (CAMLIS).

Authors:  M G Arellano; G R Petersen; D B Petitti; R E Smith
Journal:  Am J Public Health       Date:  1984-12       Impact factor: 9.308

4.  [Pharmaco-morbidity linking: a pilot study of its technical possibilities in The Netherlands].

Authors:  R M Herings; B H Stricker; A Bakker
Journal:  Ned Tijdschr Geneeskd       Date:  1990-09-29

5.  Discriminating powers of partial agreements of names for linking personal records. Part I: The logical basis.

Authors:  H B Newcombe; M E Fair; P Lalonde
Journal:  Methods Inf Med       Date:  1989-04       Impact factor: 2.176

6.  Record linkage for drug monitoring.

Authors:  D C Skegg; R Doll
Journal:  J Epidemiol Community Health       Date:  1981-03       Impact factor: 3.710

7.  Postmarketing drug surveillance by record linkage in Tayside.

Authors:  I K Crombie; S V Brown; J G Hamley
Journal:  J Epidemiol Community Health       Date:  1984-09       Impact factor: 3.710

  7 in total
  40 in total

1.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Authors:  D A M C van de Vijver; R A C Roos; P A F Jansen; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

3.  Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.

Authors:  Maurits E L Arbouw; Kris L L Movig; Cees Neef; Henk-Jan Guchelaar; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

4.  A cross-national study of the persistence of antihypertensive medication use in the elderly.

Authors:  Boris L G van Wijk; William H Shrank; Olaf H Klungel; Sebastian Schneeweiss; M Alan Brookhart; Jerry Avorn
Journal:  J Hypertens       Date:  2008-01       Impact factor: 4.844

5.  Effect of drug combinations on admission for recurrent myocardial infarction.

Authors:  Menno E van der Elst; Marcel L Bouvy; Cornelis J de Blaey; Anthonius de Boer
Journal:  Heart       Date:  2007-05-13       Impact factor: 5.994

6.  Coffee and tea consumption and risk of type 2 diabetes.

Authors:  S van Dieren; C S P M Uiterwaal; Y T van der Schouw; D L van der A; J M A Boer; A Spijkerman; D E Grobbee; J W J Beulens
Journal:  Diabetologia       Date:  2009-09-01       Impact factor: 10.122

7.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

8.  Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs.

Authors:  Miriam C J M Sturkenboom; Wim G Goettsch; Gino Picelli; Bas in 't Veld; Don D Yin; Romy B de Jong; Peter M N Y H Go; Ron M C Herings
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

9.  Change of initial oral antidiabetic therapy in type 2 diabetic patients.

Authors:  Arian Plat; Fernie Penning-van Beest; Sophia Kessabi; Martijn Groot; Ron Herings
Journal:  Pharm World Sci       Date:  2009-08-20

10.  A population based case-cohort study of drug-induced anaphylaxis.

Authors:  M M van der Klauw; B H Stricker; R M Herings; W S Cost; H A Valkenburg; J H Wilson
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.